Insulin degludec — new generation of longacting basal insulin analog (literature review and own data)
The use of first generation basal insulin analogues has certain limitations due to their pharmacokinetic and pharmacodynamic properties, relatively high risk of hypoglycemia and influence on the patient’s body weight, and require a strict dosage regimens associated with lifestyle limitations. Insulin degludec (Tresiba®) is a new basal insulin with an…
